Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.20.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating Expenses:    
Research and development $ 1,667 $ 9,067
Selling, general and administrative 9,790 12,487
Loss on impairment 4,599 228,515
Total operating expenses 16,056 250,069
Loss from Operations (16,056) (250,069)
Other income (expense)    
Loss on disposal of assets (20,463) 0
Interest expense/income (2,128) (9,117)
Total Other Income (Expense) (22,591) (9,117)
Loss before provision for income taxes (38,647) (259,186)
Provision for income taxes 0 0
Net loss $ (38,647) $ (259,186)
Weighted average shares outstanding    
Net loss per common share - basic and diluted $ (0.67) $ (5.16)
Net income (loss) per share    
Weighted average common shares outstanding - basic and diluted 57,527 50,240